[SMLE] What Is in the Neuromuscular Junction Literature?

[RSS-Bot]

J Clin Neuromuscul Dis. 2023 Dec 1;25(2):107-114. doi: 10.1097/CND.0000000000000456.

ABSTRACT

This update covers several articles on diagnosis and misdiagnosis of myasthenia gravis (MG), the role of complement in MG, and then an impressive number of recent treatment trials. There is a negative study on any corticosteroid-sparing effect of intravenous immunoglobulin. A number of positive studies are reviewed. Open-label extension studies of phase 3 trials showed benefit regarding quality of life with efgartigimod and in functional measures with ravulizumab. The phase 3 RAISE trial of zilucoplan, a self-administered complement C5 inhibitor, is covered as well as the MyCarinG trial of rozanolixizumab. The notion of using fast-acting therapies early in the course of MG is addressed. The last sections center on MG and Lambert-Eaton myasthenic syndrome as a consequence of immune checkpoint inhibitor therapy.

PMID:37962198 | DOI:10.1097/CND.0000000000000456


Source: https://pubmed.ncbi.nlm.nih.gov/3796219 ... t6+86293ac